The CCN family of proteins

The CCN family of proteins emerged as an integrated entity in 2003, when a unified nomenclature was adopted by the scientific community to reduce growing confusion in the literature (Brigstock et al. 2003). The first letter from the three founding members, which include \(\text{Cyr}~61\) (cysteine rich 61), \(\text{CTGF}\) (connective tissue growth factor) and \(\text{Nov}\) (nephroblastoma overexpressed), was used to create the acronym CCN.
IGFBP proteins became known as CCN1, CCN2 and CCN3, respectively, and three additional members were also identified at that time, including CCN4 (WISP-1), CCN5 (WISP-2) and CCN6 (WISP-3). Based on a similar domain structure, these six members have been grouped into the CCN family of matricellular proteins.

**CCN3, the nephroblastoma overexpressed gene**

As its original name suggests, CCN3 was first discovered as a gene that was overexpressed in a myeloblastosis-associated virus (MAV-1)-induced nephroblastoma that developed in chicken (Joliot et al. 1992). CCN3 is a cysteine-rich secretory protein that associates with components of the extracellular matrix. Since the discovery of this matricellular protein, CCN3 has been implicated in an increasing number of diverse biological processes including proliferation, differentiation and angiogenesis as well as pathological conditions such as fibrosis and cancer (Perbal 2001; Briggs 2003; Leask and Irvine 2009; Zuo et al. 2010; Kular et al. 2011). This diversity of CCN3 function is not surprising given the modular nature of CCN family members, which contains four distinct domains that enable binding to numerous protein partners. Layered on top of this large protein interaction network, is the growing appreciation for the importance of differential splicing and post-translational modifications, such as glycosylation and proteolytic cleavage, which can greatly influence CCN3 activity. Emerging evidence positions CCN3 as an important modulator of cancer progression and metastasis. Thus, we will focus this review specifically on these aspects of CCN3 biology as they relate to normal bone turnover, the growth of primary bone tumors and cancers that metastasize to bone.

**The modular structure of CCN3**

With one exception, all CCN family members possess an N-terminal signal peptide (SP) followed by four modular domains with homology to an insulin-like growth factor binding protein (IGFBP) domain, a von Willebrand factor type C domain (VWC), a Thrombospondin-1 type repeat (TSP-1) and a C-terminal region (CT) containing a cysteine knot structure. CCN5 is the only family member that deviates from this overall domain organization due to the absence of the CT domain (Pennica et al. 1998; Zhang et al. 1998). In each case, the VWC and TSP-1 domains are separated by a variable hinge region (Fig. 1).

**IGFBP domain** The importance of this module as a functional Insulin-like Growth Factors (IGF) binding domain in CCN proteins, and its biological significance, remains unclear. Three independent investigations have shown that CCN3 protein lacks or exhibit very low binding affinities for IGF (Kim et al. 1997; Burren et al. 1999; Vorwerk et al. 2002). The core members of the IGFBP family contain both an N- and C-terminal IGF binding domain, which act in concert to promote high affinity ligand binding (Payet et al. 2003). In contrast, CCN proteins possess a single N-terminal IGFBP domain. Thus, the 100-fold reduction in IGF binding exhibited by CCN proteins, relative to IGFBPs, was postulated to be due to the lack of this C-terminal IGF binding domain. However, a chimeric protein created by substituting the N-terminal IGFBP domain of IGFBP-3 with the N-terminal IGFBP domain of CCN3 displayed very weak binding to IGFs similar to that observed for CCN3. These data argue that the CCN3 IGFBP domain is non-functional for binding IGFs, even in the context of an N- and C-terminal IGFBP domain configuration (Yan et al. 2006).

**VWC domain** This domain, also known as chordin-like cysteine rich repeat, is commonly found in extracellular matrix proteins. The VWC module was shown to be important for the ability of CCN family members to bind Bone Morphogenetic Protein (BMP) and Transforming Growth Factor beta (TGF-β) (Abreu et al. 2002). In addition, it has been suggested that this domain plays a role in oligomerization with members of the CCN family and a diverse array of other proteins.
of interacting proteins (Voorberg et al. 1991; Brigstock 1999; Perbal 2001).

Hinge region This region connects the VWC domain to the TSP-1 like domain and is believed to be highly susceptible to proteolytic processing. It was recently shown that Kallikrein related peptidase 12 preferentially cleaved CCN1 within the hinge region, although this protease, when incubated in vitro with different recombinant CCN proteins, including CCN3 displayed multiple target sites for cleavage (Guillon-Munos et al. 2011). Additional proteins, including Elastase, Plasmin and Matrix Metalloproteases (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 and MMP-13), have all been described to cleave CCN family proteins in vitro (Brigstock et al. 1997; Hashimoto et al. 2002; de Winter et al. 2008). While the relationship between processing events that have been described in vitro to those that occur naturally need to be further clarified, these cleaved CCN variants and/or their ratio to the full length protein are thought to significantly impact the functions of CCN family members.

TSP-1 domain This domain is commonly found in a variety of extracellular matrix proteins. Within the CCN family, this region functions as a protein interaction domain that facilitates binding to Vascular Endothelial Growth Factor (VEGF) (Inoki et al. 2002), integrin receptors and Low-density Related Lipoprotein (LRP) (Gao and Brigstock 2003). These various interactions have been shown to be important for the ability of CCN family members to control tumor angiogenesis and breast cancer cell adhesion (Ellis et al. 2003; Gao and Brigstock 2003; Lin et al. 2005; Tong and Brigstock 2006)(reviewed in (Holbourn et al. 2009)).

CT domain The C-terminal module was named based on the presence of a cysteine knot structure and is known to bind a variety of proteins such as platelet-derived growth factor, nerve growth factor, TGF-β, Heparin, Heparan Sulfate Proteoglycans (HSPGs), Notch1 and Fibulin-1C (Brigstock et al. 1997; Kireeva et al. 1997; Chevalier et al. 1998; Perbal et al. 1999; Sakamoto et al. 2002; Ball et al. 2003). In addition, this module promotes homo- or heterodimerization of CCN proteins (Perbal et al. 1999; Lazar et al. 2007). The CT domain also contains a nuclear localization signal, which has been implicated in promoting interactions between CCN proteins with transcription regulatory proteins (Mahony et al. 1999; Perbal 1999; Planque et al. 2006). The functional implications of nuclear functions are not yet fully elucidated.

Thus, it is clear that the modular domain structure of CCN3 permits diverse protein interactions with members of the CCN family, which may explain why these proteins elicit different cellular responses depending on the cellular context.

CCN3 isoforms

The complexity surrounding CCN3 is, in part, related to the different alternative splice variants and post-translational modifications that alter CCN3 biological function (Perbal 2009). Several variants of CCN3 have been described in the literature; however, their origins are not well described. Thus, it is a challenge to determine whether these variants result from alternate splicing or proteolytic cleavage or other post-translational modifications. The human CCN3 is composed of 357 amino acids with a predicted size of 44 kDa. It possesses two putative N-glycosylation sites, one at position 97 (NQTG) and the second at 280 (NCTS), which results in a secreted CCN3 protein with an apparent molecular weight of 54 kDa (Chevalier et al. 1998). Thus, higher molecular weight CCN3 isoforms result from post-translational glycosylation and the lower molecular weight species are likely derived from alternative splicing or proteolytic cleavage.

The first CCN3 variant to be described was an amino-terminal truncation that resulted from integration of the MAV virus, which removed the signal peptide and the IGFBP domain, leaving only the last three modules (VWC, TSP-1 and CT) (Joliot et al. 1992). This CCN3 variant was expressed in chicken embryo fibroblasts and exhibited transforming properties. While it is unclear whether this isoform occurs naturally, it represents the first evidence of a truncated form of CCN3 that retains biological activity.

Alternative splicing Different studies have reported CCN3 variants that most likely arise from alternative splicing (reviewed in (Perbal 2009)). Although consensus sequences defining alternative splice sites have yet to be described for CCN3, they have been identified in CCN1 (Martinerie et al. 1997; Leng et al. 2002; Hirschfeld et al. 2009) and CCN4 (Tanaka et al. 2001, 2003; Cervello et al. 2004; Yanagita et al. 2007). However, the use of domain specific antibodies has facilitated the identification of two CCN3 isoforms. One lacks the TSP-1 domain and was reported to be localized in the nucleus of kidney cancers (Subramaniam et al. 2008). The other isoform of CCN3, devoid of the VWC module, was detected in Ewing sarcoma cancer cells as well as in developing mouse tissues (Heath et al. 2008; Perbal et al. 2009). While the presence of these CCN3 isoforms is intriguing, their precise biological roles have yet to be elucidated.

Proteolytic processing Numerous publications have reported proteolytically cleaved forms of CCN3 (reviewed in (Perbal 2001)). However, only one group has investigated the specific nature of the cleavage event. Following CCN3 overexpression in Sf9 insect cells, a secreted protein of 44 kDa was identified that was compatible with full-length
CCN3. In addition, a shorter 25 kDa form was found in the insect cell conditioned media and was found to correspond to the TSP-1 and CT domain (Perbal et al. 1999). N-terminal microsequencing revealed that this CCN3 isoform resulted from a cleavage event at amino acid 187, which is located within the hinge region of CCN3. A truncated protein corresponding to this size was also reported in canine MDCK cells, HeLa human cervical cancer cells and BTK-143 human osteosarcoma cells (Perbal 1999).

Several investigators have detected the presence of a protein doublet migrating at 30 and 32 kDa in various embryonic and adult tissues as well as several cancers. Amino-truncated CCN3 variants of this size were reported in diverse biological fluids, conditioned media, cytoplasm and nucleus of several cell types [for example (Chevalier et al. 1998; Burren et al. 1999; Perbal 1999; Ellis et al. 2000; and nucleus of several cell types [for example (Chevalier et al. 1998; Burren et al. 1999; Perbal 1999; Ellis et al. 2000; and nucleus of several cell types [for example (Chevalier et al. 1998; Burren et al. 1999; Perbal 1999; Ellis et al. 2000; McCallum et al. 2006; Vallacchi et al. 2007; Su et al. 2001; Thomopoulos et al. 2001; Fu et al. 2004; Kyurkchiev et al. 2004; McCallum et al. 2006; Vallacchi and Rodolfo 2009)]. Finally, in brain and adrenal tissues from the adult rat, isoforms of 38–40 kDa and 18 kDa were observed and correspond to N-terminally truncated proteins. It was proposed that these isoforms are derived from proteolysis and/or glycosylation of the CCN3 protein (Su et al. 2001).

It is clear that multiple isoforms of CCN3 exist, which arise through alternative splicing or proteolytic processing. It is less clear what effect these alternative CCN3 forms have on biological responses to CCN3. Thus, it is conceivable that the relative abundance of full length CCN3 to variant CCN3 will dramatically influence how cells respond to this protein and this underexplored aspect of CCN3 biology may account for some apparent discrepancies in CCN3 action in various cell types.

**CCN3 functions in normal bone physiology**

Of the cell types that reside in the bone microenvironment, osteoblasts are the bone forming cells and osteoclasts are responsible for resorbing bone. Mesenchymal stem cells differentiate into osteoblasts through a multi-step process (Fig. 2a) that is stimulated by BMP and Wnt family members and inhibited via Notch1 signaling (reviewed in (Krishnan et al. 2006; Canalis 2008; Long 2011)). The proper differentiation of precursors into osteoblasts requires expression of the Runx2 transcription factor, which acts as a master regulator of this process (Marie 2008).

Following stimulation with factors such as Macrophage Colony Stimulating Factor (M-CSF) and Receptor Activator of NF-kB Ligand (RANKL), hematopoietic precursors differentiate into mature activated osteoclast (Boyle et al. 2003). This process can be impaired by Osteoprotegerin (OPG), a soluble decoy receptor for RANKL. The tight control of the ratio between RANKL and OPG is critical for maintaining homeostasis of the bone (Khosla 2001; Dougall and Chaisson 2006; Ooi et al. 2011). The highest level of RANKL is secreted from osteoblast precursors and its expression decreases during osteoblast differentiation whereas OPG levels are low in osteoprogenitors and increase during osteoblastogenesis (Gori et al. 2000). In addition to RANKL and OPG, calcium signaling is critical for osteoclast differentiation, in part through its ability to induce nuclear localization of Nuclear Factor of Activated T cells c1 (NFATc1), an important transcription factor for osteoclastogenesis (Negishi-Koga and Takayanagi 2009).

Several members of the CCN family have been shown to regulate the differentiation of bone cells (Schutze et al. 2005; Kawaki et al. 2008; Su et al. 2010) (reviewed in (Yamaguchi et al. 2008; Katsube et al. 2009b; Arnott et al. 2011)). Indeed, CCN proteins are related to known antagonists of BMP proteins, such as Twisted Gastrulation (Tsg) and Chordin (Garcia Abreu et al. 2002). Until recently, a role for CCN3 in regulating the differentiation and function of bone resident cells was not known. However, the activity of CCN1 and CCN2 in these processes, coupled with the identification of certain CCN3 interacting proteins such as BMP and Notch, raised the possibility that CCN3 may also regulate bone homeostasis.

To determine whether CCN3 also plays important roles in the bone, mice overexpressing CCN3 in osteoblasts, under control of the osteocalcin promoter, were generated and characterized (Rydziel et al. 2007). Two independent transgenic lines were analyzed; the first exhibiting CCN3 expression in calvarial extracts that ranged between 25 and 250 times the levels detected in non-transgenic controls. Male and female mice, which were heterozygous for the transgene, displayed a 30–35% decrease in trabecular bone volume but exhibited similar numbers of osteoblasts, osteoclasts and similar degrees of bone erosion. However, diminished mineral apposition and bone formation was observed, which suggested impaired osteoblast function. In the second transgenic line, CCN3 mRNA expression ranged from 1,000 to 9,000-fold higher when compared to the wild type control mice. Animals from this transgenic line suffered from osteopenia, a condition characterized by significantly diminished bone mineral density. This phenotype was correlated with an increase in bone resorption and elevated osteoclast numbers along the eroded bone surfaces. These data argue that CCN3 plays a significant role in suppressing osteoblast differentiation and, at high concentrations, may enhance osteoclast differentiation or function.

This conclusion was further supported by phenotypes associated with mice bearing a targeted disruption in the CCN3 gene. These mice were engineered to express a CCN3del3 mutant, which encoded a protein lacking the VWC domain (Heath et al. 2008). While full length CCN3 could not be detected in these animals, the CCN3del3
protein was present at low but detectable levels. Interestingly, a transcript lacking the VWC domain was also present in several tissues of the wild-type embryos, raising the possibility that this isoform of CCN3 could arise naturally from alternative splicing. In CCN3del3 expressing embryos, the skeleton showed abnormalities such as enlarged vertebrae, elongated long bones and digits. In addition, joint defects such as fusions, malformations, dislocations and laxity were observed in mice expressing CCN3del3. In adult animals, overgrowth of the bone and joint defects were also reported. These data argue that the normal role for CCN3 is to suppress bone formation by osteoblasts, and that the loss of CCN3 resulted in excessive bone formation. However, the authors could not definitively conclude that skeletal phenotypes observed in the CCN3del3 mice resulted from the loss of CCN3 or to a new function ascribed to the truncated CCN3del3 protein (Heath et al. 2008).

More recently, a complete knock-out of CCN3, in which exons 1, 2 and a portion of exon 3 were removed, has been described (Shimoyama et al. 2010). No overt skeletal phenotypes were reported in these CCN3−/− mice; however, this study focused primarily on the role of CCN3 in the vasculature (Shimoyama et al. 2010). Another CCN3 null mouse has been developed, where the entire coding sequence of CCN3 was deleted (Canalis et al. 2010). CCN3 null mice did not demonstrate skeletal abnormalities during development and only very modest bone defects were observed with low penetrance. For example, an increase in osteoblast numbers/bone surface, mineralization and bone formation was apparent in ten-month-old females; however, this phenotype was not evident in males of the same age (Canalis et al. 2010).

Another interesting aspect of CCN action within the bone microenvironment is their potential roles in the fracture repair process. Indeed, CCN1, CCN2 and CCN4 have all been shown to be overexpressed during various phases of the fracture repair process (Hadjijarygrou et al. 2002; Nakata et al. 2002; French et al. 2004). Moreover, blocking antibodies against CCN1 disrupt fracture healing, providing evidence that CCN family members play a functional role in this process (Athanasopoulos et al. 2007). To date, no studies have implicated CCN3 in fracture repair and...
represent an interesting avenue of investigation that would further clarify the influence of CCN3 on bone resident cells.

Taken together, these data argue that CCN3 can influence osteoblast, and potentially osteoclast, differentiation and/or function. However, it is clear that CCN3 exerts the greatest effects on bone formation/remodeling when it is overexpressed, rather than when physiological levels of CCN3 are lost. Another important aspect when evaluating the role of CCN3 in bone is the expression level of the other CCN family members, including CCN1 and CCN2. For example, studies on CCN2<sup>−/−</sup> mice revealed that CCN3 becomes overexpressed in a context of CCN2 knock-out (Kawaki et al. 2008). Considerations such as these may be important in understanding CCN3 action in bone and begin to shed light on factors that may influence the cellular context in which CCN3 can exert its biological effects.

**Mechanisms of CCN3 action in osteoblasts**

The above studies argue that CCN3 regulates osteoblast differentiation. While several of these in vitro studies suggest that CCN3 can negatively regulate osteoblast differentiation, the mechanisms underlying CCN3 action have been revealed using in vitro cell culture systems. Using a MC3T3 murine calvarial derived cell model, which can be induced to differentiate into osteoblast-like cells, CCN3 was shown to inhibit osteoblast differentiation by binding to and neutralizing BMP2, a well-known enhancer of osteoblastogenesis (Minamizato et al. 2007). This led to diminished mRNA expression of several BMP2 target genes, such as Runx2, Osterix, Alkaline Phosphatase (ALP) and Osteocalcin. In addition, CCN3 was also shown to augment the release of the Notch Intracellular Domain (NICD) from full length Notch, leading to an increase in Hairy/Enhancer of Split (HES) and Hairy/Enhancer of Split with YRPW motif 1 (HEY) transcription and ultimately to impaired osteoblast differentiation (Minamizato et al. 2007).

In another study, CCN3 overexpression in ST-2 cells, a stromal cell line derived from mouse bone marrow, also resulted in a block in osteoblast differentiation (Rydziel et al. 2007). CCN3-expressing ST-2 cells displayed reduced numbers of mineralized nodules and diminished levels of Smad-1, Smad-5, and Smad-8 phosphorylation when these cells were stimulated with BMP2. In this cell system, CCN3 exerted these effects by directly binding and neutralizing BMP2 and through impairment of Wnt3 signaling (Rydziel et al. 2007). Likewise, using ST-2 and MC3T3 cells, CCN3 was shown to impair osteoblast differentiation through BMP2 neutralization and impairment of Wnt3 signaling, in a Notch independent manner (Canalis 2007).

Yet another potential mechanism has been proposed to account for CCN3-mediated impairment of osteoblast differentiation. Overexpression of CCN3 in ST-2 cells leads to increased Gremlin expression, a known BMP2 antagonist (Gazzarro and Canalis 2006), through a mechanism involving Gremlin mRNA stabilization (Smerdel-Ramoya et al. 2011). Thus, CCN3 can function to blunt BMP2 action by directly binding and neutralizing BMP2 or through indirect mechanisms that involve stabilization of BMP2 antagonists.

CCN3 was shown to decrease proliferation and osteoblast differentiation of Kusa-A1 osteogenic mesenchymal stem cells through Notch-1 mediated p21 upregulation. This inhibitory function was also dependent on CCN3’s ability to bind directly to BMP2. These results argued that the ability of CCN3 to bind BMP2 in a CT domain independent manner is an important mechanism through which it can block osteoblast differentiation (Katsuki et al. 2008; Katsube et al. 2009a).

These findings are supported by the observation that primary calvarial bone marrow cells from CCN3<sup>−/−</sup> mice revealed enhanced osteoblast differentiation in response to BMP2 when compared to cultures from wild-type controls (Canalis et al. 2010). Moreover, in both ST-2 and MC3T3 cells, siRNA-mediated reduction of CCN3 expression led to an increase in ALP expression and enhanced activity of a BMP reporter construct following BMP2 treatment. In agreement with previous results, CCN3 was shown to bind directly to BMP2. When investigating osteoclast differentiation, calvarial cultures from CCN3<sup>−/−</sup> mice displayed higher numbers of osteoclasts when vitamin D3 was used as an inducer of osteoclastogenesis, raising the possibility that CCN3 suppresses osteoclast differentiation as well (Canalis et al. 2010).

Together, these data support a role for CCN3 as an inhibitor of osteoblast differentiation through multiple mechanisms, which include interfering with BMP2 and/or Wnt/β-Catenin signaling or via activation of the Notch1 pathway (Fig. 2) (Canalis 2007; Rydziel et al. 2007; Yamaguchi et al. 2008; Smerdel-Ramoya et al. 2011). It should be noted that not all studies are in agreement with a role for CCN3 in negatively regulating osteoblast differentiation. In fact, a recent study demonstrated that CCN3 favors osteoblast differentiation and bone mineralization by inducing the expression of BMP-4, a potent inducer of osteoblast differentiation. These CCN3-mediated effects were dependent on α5β1 and αvβ5 integrin receptors and subsequent activation of Integrin Linked Kinase (ILK), p38 and c-Jun Kinase (JNK) (Tan et al. 2011). Interestingly, the concentrations of CCN3 (3–30 ng/ml) that induced osteoblast differentiation were much lower when compared to CCN3 concentrations (300–600 ng/mL) that blocked osteoblast differentiation (Rydziel et al. 2007; Ouellet et al. 2011; Tan et al. 2011). These observations are reminiscent of the in vivo data, which revealed different effects depending on whether CCN3 was present in physiological levels or whether it was overexpressed.
CCN3 in primary bone cancers

Osteosarcoma Osteosarcoma is comprised of a group of neoplasms that are usually of high grade and stage when diagnosed. They are thought to originate from mesenchymal cells having osteoblastic features. The incidence of this cancer is low in the general population although it is the most diagnosed and lethal bone cancer in young adults (Tang et al. 2008). CCN3 expression in osteosarcoma cell lines is variable. Immunohistochemistry performed on musculoskeletal tumors reveal high CCN3 expression in osteoblasts, osteoclasts, chondrocytes and skeletal muscle cells. Interestingly, primary tumors of osteosarcoma patients, who developed lung metastases, presented with high CCN3 expression (Manara et al. 2002).

Using osteosarcoma derived cell lines; CCN3 expression was found to be inversely correlated with ALP expression (Manara et al. 2002). It is known that osteosarcomas are characterized by impaired osteoblastic differentiation and generally lack markers of terminal differentiation, which has been associated with disrupted Runx2 function (Thomas et al. 2004). Interestingly, forced expression of CCN3 in normal osteoblasts can result in Notch pathway driven inhibition of Runx2 (Minamizato et al. 2007). Moreover, CCN3 has been shown to be upregulated in osteoblast-like osteosarcoma Saos-2 and OS7 cell lines (Perbal et al. 2008). Thus, it has been hypothesized that high CCN3 expression in osteosarcoma might activate Notch signaling, resulting in osteosarcoma cells being locked into an early stage of osteoblastic differentiation. In agreement with this hypothesis, CCN3 mRNA levels are increased in osteosarcoma cell lines and tumor tissues when compared to osteoblasts. Indeed, high CCN3 expression in osteosarcomas was not associated with osteoblast differentiation markers and, more importantly, correlated with shorter disease free survival (Perbal et al. 2008). This clinical correlation is in agreement with the recent observation that CCN3 can enhance the migratory properties of osteosarcoma cells, which involves \( \alpha_v\beta_5 \) integrin-mediated upregulation of COX-2 expression (Huang et al. 2011).

Ewing’s sarcoma Ewing’s sarcoma is the second most commonly diagnosed bone tumor and is found in rapidly growing bone of children (Jurgens and Dirksen 2011). While CCN3 is expressed in approximately 30% of Ewing’s sarcomas, it is associated with shorter disease free survival (Manara et al. 2002). Ewing’s sarcoma cell line (TC71) engineered to overexpress CCN3 displayed decreased cell proliferation \textit{in vitro}, growth in soft agar and tumorigenicity when injected into mice (Benini et al. 2005). However, these CCN3-expressing cells showed increased migration and invasion using Boyden chamber assays. Increases in cell invasion were correlated with increased levels of MMP9 associated with the cell surface (Benini et al. 2005). MMP9 was previously shown to trigger the switch between the stationary and migratory state by altering cytoskeleton rearrangement through activation of RhoA/Paxillin/\( \beta \)-catenin signaling (Sanceau et al. 2003). In addition, overexpression of CCN3 caused a decrease in cancer cell adhesion to collagen I and collagen IV, which might be due to decreased levels of \( \alpha_2\beta_1 \) integrin. However, no significant differences
were seen in the ability of Ewing’s sarcoma cells to adhere to Laminin, Fibronectin or Vitronectin (Benini et al. 2005). Immunohistochemistry on 170 human Ewing’s sarcoma samples revealed that CCN3 was more highly expressed in recurrences (6/8) and metastases (8/10) when compared to the primary tumor (79/152). Microarray analyses on 30 Ewing’s tumors, coupled with immunohistochemistry on 125 cases that possessed sufficient clinical data and follow-up, revealed that low levels of CCN3 expression were associated with better patient prognosis when disease free and overall survival was considered. Interestingly, domain specific antibodies revealed that 41% of the tumors expressed a protein lacking the VWC domain. Expression of this truncated protein confers a better prognosis to the patient (Perbal et al. 2009).

**Chondrosarcoma** Chondrosarcoma are malignant tumors of cartilage tissue that do not respond well to chemotherapy or radiotherapy treatment (Jamil et al. 2010). CCN3 expression in chondrosarcoma was reported to be higher in well-differentiated tumors and associated with a better patient prognosis (Manara et al. 2002; Yu et al. 2003; Benini et al. 2005). Immunohistochemical analyses revealed that infiltrates of giant-cells within chondrosarcomas exhibited strong staining of CCN3 (Manara et al. 2002). Studies on a chondrosarcoma-derived cell line showed that CCN3 increases their migration and up-regulates MMP-13 expression and activity. CCN3-induced migration was associated with engagement of the αvβ5 and αvβ3 integrins and subsequent activation of Focal Adhesion Kinase, Phosphatidylinositol 3- kinase, Akt and NF-κB signaling pathways (Tzeng et al. 2011).

These data reveal that CCN3 can play diverse roles in modulating the malignant phenotype in primary bone cancers. In osteosarcoma, CCN3 enhances the malignant phenotype of these cancer cells by limiting the extent of osteoblastic differentiation and promoting their migratory and invasive properties. Similarly, high CCN3 expression is also associated with a poor outcome in Ewing’s Sarcoma and elicits enhanced migratory and invasive responses in these cells. In contrast, CCN3 expression has been associated with a more differentiated phenotype and better prognosis in chondrosarcoma. These differences likely reflect the role played by CCN3 in the normal differentiation programs of chondrocytes and osteoblasts. CCN3 is a positive regulator of chondrocyte differentiation through the induction of TGF-β2, which is important during the condensation stage of chondrocyte differentiation (Kawai et al. 1999). Moreover, TGF-β1 functions to impair chondrocyte differentiation (Valcourt et al. 2003), and has been shown to diminish CCN3 levels (Parisi et al. 2006). In contrast, CCN3 acts as a negative regulator of osteoblast differentiation. Thus, the prognostic significance of CCN3 may be linked to its normal role during the differentiation of these bone resident cells.

**CCN3 expression in bone metastatic cancers**

The vast majority of cancers affecting bone are not derived from primary bone tumors, but rather metastatic cancer cells that have spread from distant organs to colonize the bone. The two solid cancers that metastasize with the highest frequency to bone include breast and prostate cancer. Given the effects CCN3 has on the differentiation and function of bone resident cells, it may not be surprising that CCN3 has been implicated in the progression of these cancers as well.

**Breast cancer** Breast cancer is the most frequently diagnosed cancer in North American woman. Immunohistochemical staining of CCN3 in normal breast tissue, CCN3 reveals intense staining in epithelial cells, with weaker immune-positivity in the stroma and endothelium (Jiang et al. 2004). Several reports have investigated the association of CCN3 expression with clinical parameters of patients with breast cancer. In one small study, CCN3 transcript levels did not correlate with clinical parameters such as age of the patient, hormone receptor and HER2 status, grade, stage, lymph node involvement or tumor size. Only a fraction (5/44) of samples displayed higher levels of CCN3 in the tumor compared to normal breast tissue (Xie et al. 2001). In a different cohort of 122 human breast tumors and 32 normal breast tissues, lower CCN3 mRNA and protein levels were observed in tumor tissues when compared to normal samples. In addition, CCN3 expression was significantly lower in tumors of high grade in those patients diagnosed at advanced stage of the disease (Jiang et al. 2004). These studies argue that high CCN3 expression in breast cancers is associated with a better outcome.

In breast cancer-derived cell lines, low expression of CCN3 was also reported in the aggressive MDA-MB-231 human cell line when compared to the less invasive MCF-7 line (Jiang et al. 2004). Using MCF-7 cell line as a breast cancer model, CCN3 was reported to be a direct target of estrogen. Indeed, CCN3 expression was repressed in MCF-7 cells following treatment with estrogen (17-β-estradiol) (Vendrell et al. 2004). Breast cancers that express the Estrogen Receptor (ER) are classified as luminal breast cancers and stratify patients for disease management using anti-estrogen therapies such as tamoxifen (Girdler and Brotherick 2000). However, a portion of patients with ER + disease are intrinsically resistant to Tamoxifen and the majority of patients that initially respond to anti-estrogen therapies will develop resistance. Interestingly, CCN3 expression was found to be elevated in a sub-population of MCF-7 cells (MVLN) that were selected for resistance to tamoxifen or fulvestrant (Demirpence et al. 1993; Ghayad et al.

© Springer
Moreover, CCN3 was highly expressed in breast cancers from patients who had relapsed following tamoxifen treatment versus tumors from those that did not. In addition, CCN3 was one of five genes associated with shorter disease free survival in ER+ patients treated with Tamoxifen (Ghayad et al. 2009).

As mentioned previously, the effects of CCN3 can be context dependent. Thus it has been shown that overexpression of CCN3 in MDA-MB-231 breast cancer cells results in reduced growth but has no effect on breast cancer cell adhesion to Collagen I, Collagen IV, Fibronectin or Vitronectin. Rather, CCN3 expression enhanced the ability of MDA-MB-231 cells to form spheroids in 3-D culture through increased intercellular adhesion. Interestingly, full length CCN3 was unable to induce the migration of MDA-MB-231 cells, whereas a CCN3 mutant lacking the CT domain was able to induce a migratory phenotype. These observations highlight the diversity of responses elicited by CCN3 in different cell types, even between ER+ and ER- subtypes of breast cancer (Sin et al. 2009).

Relatively little is known about the role of CCN3 in metastatic breast cancer. The first hint that CCN3 may play a role in organ-specific metastasis came from the analysis of gene expression profiles derived from 58 breast cancer metastases. Interestingly, CCN3 was found to be highly expressed in the majority of the bone (16 samples) metastases but was detected at very low levels in metastases derived from lung (18 samples), brain (19 samples) and liver (5 samples) (Zhang et al. 2009).

In our own work, we also have shown that CCN3 is expressed in bone metastasis samples from patients with breast cancer and have identified CCN3 as a gene highly expressed at the mRNA and protein levels in 4T1 murine breast cancer cells selected for their ability to metastasize to bone (Rose et al. 2007; Ouellet et al. 2011). We also demonstrated that CCN3 enhanced the bone metastatic ability of 66cl4 cells, which are known only to metastasize to the lungs, without altering their growth in the mammary fat pad (Ouellet et al. 2011). Our interest in CCN3 as a factor that could promote the formation of osteolytic bone metastases stemmed from its demonstrated roles in regulating the differentiation and activity of bone resident cells, as discussed above. During the formation of osteolytic lesions, the balance between bone formation and resorption is tipped in favor osteoclast differentiation and bone destruction. In agreement with previous studies, CCN3 was able to impair osteoblast differentiation from primary bone marrow cultures, resulting in higher RANKL/OPG ratios which would enhance osteolastogenesis. Furthermore, we demonstrated that CCN3 promotes osteoclast differentiation from RANKL-primed monocyte precursors (RAW264.7) through a mechanism involving calcium oscillations and NFATc1 nuclear translocation (Ouellet et al. 2011). Interestingly, the ability of CCN3 to promote the formation of osteolytic bone metastases may reflect the fact that breast cancer cells colonizing the bone would contribute to significantly elevated levels of CCN3, which would tip the balance towards osteolastogenesis (Fig. 3).

Recently, it has been argued that the expression level of CCN3 alone may not be the most informative, but rather the ratio of CCN3 versus CCN1 or CCN2 is more important. High CCN1/CCN3 or CCN2/CCN3 mRNA ratios were found to be associated with a highly metastatic phenotype in breast cancer cells. In addition, high expression of CCN2 relative to low CCN3 levels was associated with enhanced tumor formation, angiogenesis and the ability to form bone metastases (Ohgawara et al. 2011). This is in contrast to our findings in which we observed high CCN3 levels in the context of low CCN1 and CCN2 expression in bone metastatic breast cancer cells (Ouellet et al. 2011) and also contrasts with the observation that human breast cancer bone metastases that display high CCN3 mRNA expression (Zhang et al. 2009). One potential explanation for these differences stems from the fact that we analyzed expression of CCN family members in breast cancer cells that had formed bone metastases and were explanted back into culture (Ouellet et al. 2011); whereas, CCN1/CCN3 and CCN2/CCN3 ratios in the MDA-MB-231 model were determined in unselected parental breast cancer cells that had not formed bone metastases (Ohgawara et al. 2011). The possibility that CCN3 expression is selected for in bone metastases is substantiated by the detection of CCN3 specifically in bone metastases (Zhang et al. 2009). Indeed, the notion that, following cancer cell selection and isolation from distinct metastatic sites, the expression of genes in the selected populations can vary dramatically from the starting cell population is now widely accepted (Kang et al. 2003; Minn et al. 2005; Rose et al. 2007; Bos et al. 2009; Tabaries et al. 2011). The data supporting a high CCN2/CCN3 ratio in the bone metastases was based solely on immunohistochemical staining (Ohgawara et al. 2011). However, immunohistochemical staining in bone metastases derived from MDA-MB-231 cells cannot be used to make such quantitative arguments regarding the relative ratio of CCN2 to CCN3, given that these antibodies will undoubtedly have very different affinities for their respect targets (Ohgawara et al. 2011).

Prostate cancer Relatively little is known concerning the role of CCN3 in prostate cancer progression and metastasis. Only one study has examined CCN3 levels in prostate cancer cell lines and tissues, which revealed that CCN3 expression was higher in prostate cancer-derived cell lines compared to immortalized prostate epithelial cells (Maillard et al. 2001). It is intriguing to note that the highest level of CCN3 expression was observed in the PC3 prostate
cancers affecting bone. Furthermore, 19 of 20 prostate adenocarcinoma samples stained positively for CCN3 expression by immunohistochemistry. However, the sample size was too small to make meaningful correlations between the intensity of CCN3 staining and Gleason score (Maillard et al. 2001). The established role of CCN3 as an inhibitor of osteoblast differentiation (Canalis 2007; Minamizato et al. 2007; Rydziel et al. 2007; Katsuki et al. 2008; Yamaguchi et al. 2008; Katsube et al. 2009a; Canalis et al. 2010; Ouellet et al. 2011), coupled with the recent observation that low CCN3 concentrations may enhance osteoblastogenesis, raises the intriguing possibility that CCN3 could play a role in lytic and/or blastic bone metastases formation depending on the level of CCN3 expression. However, this will require further functional validation to determine whether CCN3 plays a functional role in prostate cancer growth and metastasis to bone.

Conclusion

CCN3 exerts numerous effects on both normal and transformed cells, and the cellular responses can be very different depending on the various CCN3 isoforms and the cellular context in which CCN3 is acting. Moreover, increasing data suggests that the ultimate outcome of cellular differentiation that is regulated by CCN3 may also depend on the level of CCN3 expression. Available data points toward an important role for CCN3 in the negative regulation of osteoblast differentiation, which has clear consequences for normal bone homeostasis and turnover. In addition, CCN3 has been implicated as a poor prognostic marker in several primary bone cancers, including osteosarcoma and Ewing’s sarcoma. Given the ability of CCN3 to modulate the differentiation status and activity of bone resident cells, it is interesting to note that breast cancer cells that metastasize to bone and induce bone destruction select for high levels of CCN3 expression. Future studies will be needed to focus on the modular domains within CCN3 that are important for the pro-bone metastatic activities of CCN3. Moreover, very little is known regarding the role of CCN3 in prostate cancer progression and subsequent metastasis to bone.

These areas represent fertile ground for future experimentation. What is clear is that CCN3 can play complex roles in modulating cancer phenotypes, such as metastasis, as it does in the regulation of normal cellular behavior. However, there is growing evidence that CCN3 can influence the progression of primary bone cancers and act as an important pro-metastatic factor in numerous cancers, including metastatic cancers affecting bone.

Acknowledgements We thank Dr. Josie Ursini-Siegel, Dr. Matthew G. Annis and Dr. Sébastien Tabaries for critical comments regarding this manuscript. Work in the author’s laboratory, which is described in the review, was supported by the Canadian Institutes of Health Research (CIHR, CTP-79857) and the Cancer Research Society. V.O. is supported by a post-doctoral fellowship from the CIHR and P.M.S is a research scholar (Junior 2) of the Fonds de recherche du Québec–Santé (FRQS).

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Abreu JG, Kepurse B, Reversade B, De Robertis EM (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4:599–604
Angelucci A, Gravina GL, Rucci N, Festuccia C, Muze P, Vicentini C, Teti A, Bologna M (2004) Evaluation of metastatic potential in prostate carcinoma: an in vivo model. Int J Oncol 25:1713–1720
Arnott JA, Lambi AG, Mundy C, Hendesi H, Pixley RA, Owen TA, Safadi FF, Popoff SN (2011) The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev Eukaryot Gene Expr 21:43–69
Athanasopoulos AN, Schneider D, Keiper T, Alt V, Pendurthi UR, Liegibel UM, Sommer U, Nawroth PF, Kasperk C, Chavakis T (2007) Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates prosangiogenic activities in endothelial cells and promotes fracture healing. J Biol Chem 282:26746–26753
Ball DK, Rachfal AW, Kemper SA, Brigstock DR (2003) The heparin-binding 10 kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion. J Endocrinol 176: R1–R7
Benini S, Perbal B, Zambelli D, Colombo MP, Manara MC, Serra M, Parenza M, Martinez V, Picci P, Scotlandi K (2005) In Ewing’s sarcoma CCN3(NOVI) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24:4349–4361
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342
Brigstock DR (1999) The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 20:189–206
Brigstock DR (2003) The CCN family: a new stimulus package. J Endocrinol 178:169–175
Brigstock DR, Steffen CL, Kim GY, Vegunta RK, Diehl JR, Harding PA (1997) Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. J Biol Chem 272:20275–20282
Buckstock DR, Goldschmeding R, Katsube KI, Lau LF, Lyons K, Naas C, Perbal B, Riser B, Takigawa M, Yeger H (2003) Proposal for a unified CCN nomenclature. Mol Pathol: 56:127–128
Burren CP, Wilson EM, Hwa V, Oh Y, Rosenfeld RG (1999) Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. J Clin Endocrinol Metab 84:1096–1103
Canalis E (2007) Nephroblastoma overexpressed (Nov) is a novel bone morphogenetic protein antagonist. Ann N Y Acad Sci 1116:50–58
Canalis E (2008) Notch signaling in osteoblasts. Sci Signal 1:pe17
Canalis E, Smerdel-Ramoya A, Durant D, Economides AN, Beamer WG, Zanotti S (2010) Nephroblastoma overexpressed (Nov) in-activation sensitizes osteoblasts to bone morphogenetic protein-2, but nov is dispensable for skeletal homeostasis. Endocrinology 151:221–233
Cervello M, Giannitrapi L, Labbozetta M, Notarbartolo M, D’Alessandro N, Lampiasi N, Azzolina A, Montalto G (2004) Expression of WISP3 and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci 1028:432–439
Chen CC, Lau LF (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41:771–783
Chevalier G, Yeger H, Martinerie C, Laurent M, Alami J, Schofield PN, Perbal B (1998) novH: differential expression in developing kidney and Wilm’s tumors. Am J Pathol 152:1563–1575
de Winter P, Leoni P, Abraham D (2008) Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 26:80–91
Demirgence E, Duches MJ, Badia E, Gagne D, Pons M (1993) MLVN cells: a bioluminescent MCE-7-derived cell line to study the modulation of estrogenic activity. J Steroid Biochem Mol Biol 46:355–364
Dougall WC, Chassion M (2006) The RANK:RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25:541–549
Ellis PD, Chen Q, Barker PJ, Metcalfe JC, Kemp PR (2000) Nov gene encodes adhesion factor for vascular smooth muscle cells and is dynamically regulated in response to vascular injury. Arterioscler Thromb Vasc Biol 20:1912–1919
Ellis PD, Metcalfe JC, Hyvonen M, Kemp PR (2003) Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alphav5beta1. J Vasc Res 40:234–243
French DM, Kaul RJ, D’Souza AL, Crowley CW, Bao M, Frantz GD, Filvaroff EH, Desnoyers L (2004) WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol 165:855–867
Fu CT, Bechberger JF, Ozog MA, Perbal B, Naus CC (2004) CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 279:36943–36950
Gao R, Brigsstock DR (2003) Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res Office J Hepatocatalauled Hepatol 27:214–220
Garcia Abreu J, Coffinier C, Larrain J, Oelgeschlager M, De Robertis EM (2002) Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287:39–47
Gazzero E, Canalis E (2006) Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7:51–65
Gayhaz SE, Vendrell JA, Biche I, Spyratos F, Dumontet C, Treilleux I, Lidereau R, Cohen PA (2009) Identification of TACCC1, NOV, and PTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol 42:87–103
Girdler F, Brotherick I (2000) The oestrogen receptors (ER alpha and ER beta) and their role in breast cancer: a review. Breast 9:194–200
Gori F, Hoebauer LC, Dunstan CR, Spielberg TC, Khosa S, Riggs BL (2000) The expression of osteoprogestin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768–4776
Guillou-Munos A, Oikonomopoulou K, Michiel N, Smith CR, Petit-Courty A, Canepa S, Reverdiau P, Heuze-Vourc’h N, Diamandis EP, Courty Y (2011) Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J Biol Chem 286:25505–25518
Hadjiajryrou M, Lombardo F, Zhao S, Ahrens W, Joo J, Ahn H, Jurman M, White DW, Rubin CT (2002) Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J Biol Chem 277:30177–30182
Hashimoto G, Inoki I, Fujiy Y, Aoki T, Ikeda E, Okada Y (2002) Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 277:36288–36295
Heath E, Tahri D, Andermarkier E, Schofield P, Fleming S, Boulter CA (2008) Abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC Dev Biol 8:18
Hirschfeld M, zur Hausen A, Bettendorf H, Jager M, Stiekeler E (2009) Alternative splicing of Cry61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res 69:2082–2090
Hollbourn KP, Perbal B, Ravi Acharya K (2009) Proteins on the catwalk: modelling the structural domains of the CCN family of proteins. J Cell Commun Signal 3:25–41
Huang CY, Lee CY, Chen MY, Tsai HC, Hsu HC, Tang CH (2011) Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves alphavbeta5 integrin, ILK and AP-1-dependent pathways. Biochem Pharmacol 81:577–585
Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y (2002) Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J Off Publ Fed Am Soc Exp Biol 16:219–221
Jamil N, Howie S, Salter DM (2010) Therapeutic molecular targets in human chondrosarcoma. Int J Exp Pathol 91:387–393
Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE (2004) Differential expression of the CCN family members Cry61, CTGF and Nov in human breast cancer. Endocr-Relat Cancer 11:781–791
Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, Perbal B (1992) Provilol rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 12:10–21
Jurgens H, Dirksen U (2011) Ewing sarcoma treatment. Eur J Cancer 47(Suppl 3):S366–S367
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Geise TA, Massagi J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549
Katsube K, Ichikawa S, Katsuki Y, Kihara T, Terai M, Lau LF, Tamamura Y, Takeda S, Umewaza A, Sakamoto K, Yamaguchi A (2009a) CCN3 and bone marrow cells. J Cell Commun Signal 3:135–145
Katsube K, Sakamoto K, Tamamura Y, Yamaguchi A (2009b) Role of CCN, a vertebrate specific gene family, in development. Develop Growth Differ 51:55–67
Katsuki Y, Sakamoto K, Minamizato T, Makino H, Umewaza A, Ikeda MA, Perbal B, Amagasa T, Yamaguchi A, Katsuki K (2008) Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem Biophys Res Commun 368:808–814
Kawai J, Akiyama H, Shigeno C, Ito H, Konishi J, Nakamura T (1999) Effects of transforming growth factor-beta signaling on chondrogenesis in mouse chondrogenic EC cells. ATDC5. Eur J Cell Biol 78:707–714
Kawah K, Kubota S, Suzuki A, Lazar N, Yamada T, Matsumura T, Ogawa T, Maeda T, Perbal B, Lyons KM, Takigawa M (2008) Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family
proteins in cartilage. J Bone Miner Res Off J Am Soc Bone Miner Res 23:1751–1764

Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055

Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts CT Jr, Rosenfeld RG (1997) Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBP): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci U S A 94:12981–12986

Kireeva ML, Latinkic BV, Kolesnikova TV, Chen CC, Yang GP, Abler AS, Lau LF (1997) Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res 233:63–77

Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202–1209

Kular L, Pakradouni J, Kitabgi P, Laurent M, Martinere C (2011) The CCN family: a new class of inflammation modulators? Biochimie 93:377–388

Kyurkchiev S, Yeger H, Bleau AM, Perbal B (2004) Potential cellular conformations of the CCN3(NOV) protein. Cell Commun Signal: CCS 2:9

Lazar N, Manara C, Navarro S, Bleau AM, Llombart-Bosch A, Scotlandi K, Planque N, Perbal B (2007) Domain-specific CCN3 antibodies as unique tools for structural and functional studies. J Cell Commun Signal 1:91–102

Leask A, Abraham DJ (2006) All in the CCN family: essential matrix-cellular signaling modulators emerge from the bunker. J Cell Sci 119:4803–4810

Leng E, Malcolm T, Tai G, Estable M, Sadowski I (2002) Organization and expression of the Cyr61 gene in normal human fibroblasts. J Biomed Sci 9:59–67

Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM, Lau LF (2005) Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem 280:8229–8237

Long F (2011) Building strong bones: molecular regulation of the osteoblast lineage. Nature reviews. Mol Cell Biol 13:27–38

Mahony D, Kalionis B, Antalis TM (1999) Plasminogen activator inhibitor type-2 (PAI-2) gene transcription requires a novel NF-kappaB-like transcriptional regulatory motif. Eur J Biochem 263:765–772

Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B, Tatoud R (2001) Differential expression of the ccn3 (nov) protein in human prostate cell lines and tissues. Mol Pathol: MP 54:275–280

Manara MC, Perbal B, Benini S, Strammielli R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, Scotlandi K (2002) The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol 160:849–859

Marie PJ (2008) Transcription factors controlling osteoblastogenesis. Arch Biochem Physiol 473:98–105

Martinere C, Viegas-Pequignot E, Nguyen VC, Perbal B (1997) Chromosomal mapping and expression of the human cyr61 gene in tumour cells from the nervous system. Mol Pathol: MP 50:310–316

McCallum L, Irvine AE (2009) CCN3—a key regulator of the hematopoietic compartment. Blood Rev 23:79–85

McCallum L, Price S, Planque N, Perbal B, Pirece A, Whetton AD, Irvine AE (2006) A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108:1716–1723

Minamizato T, Sakamoto K, Liu T, Kokubo H, Katsube K, Perbal B, Nakamura S, Yamaguchi A (2007) CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signalling pathways. Biochem Biophys Res Commun 354:567–573

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524

Nakata E, Nakanishi T, Kawai A, Asaumi K, Yamaai T, Asano M, Nishida T, Mitani S, Inoue H, Takigawa M (2002) Expression of connective tissue growth factor/hypertrophic chondrocyte-specific gene product 24 (CTGF/Hcs24) during fracture healing. Bone 31:441–447

Negishi-Koga T, Takayanagi H (2009) Ca2 +-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 231:241–256

Ohgawara T, Kubota S, Kawaki H, Kurio N, Abd El Kader T, Hoshijima M, Januse D, Shimo T, Perbal B, Sasaki A, Takigawa M (2011) Association of the metastatic phenotype with CCN family members among breast and oral cancer cells. J Cell Commun Signal

Ooi LL, Zheng Y, Stalgsis-Bilinski K, Dunstan CR (2011) The bone remodeling environment is a factor in breast cancer metastasis. Bone 48:66–70

Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel PM (2011) CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol 178:2377–2388

Parisi MS, Gazzero E, Rydziel S, Canalis E (2006) Expression and regulation of CCN genes in murine osteoblasts. Bone 38:671–677

Payet LD, Wang XH, Baxter RC, Firth SM (2003) Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions. Endocrinology 144:2797–2806

Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ (1998) WISP genes are members of the connective tissue growth factor family that are up-regulated in wt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95:14717–14722

Perbal B (1999) Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression. Mol Pathol: MP 52:84–91

Perbal B (2001) NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol: MP 54:57–79

Perbal B (2006) NOV story: the way to CCN3. Cell Commun Signal: CCS 4:3

Perbal B (2009) Alternative splicing of CCN mRNAs .... it has been upon us. J Cell Commun Signal 3:153–157

Perbal B, Takigawa M (2005) CCN proteins: a new family of cell growth and differentiation regulators. Imprperial College Press

Perbal B, Martinere C, Sainson R, Werner M, He B, Roizman B (1999) The C-terminal domain of the regulatory protein NOV is sufficient to promote interaction with fibulin 1C: a clue for a role of NOV in cell-adhesion signaling. Proc Natl Acad Sci U S A 96:869–874

Perbal B, Zumin I, Zambelli D, Serra M, Sciairda M, Cantiani L, Lucarelle E, Picci P, Scotlandi K (2008) Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res Off J Am Assoc Cancer Res 14:701–709

Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, Picci P (2009) Prognostic relevance of CCN3 in Ewing sarcoma. Hum Pathol 40:1479–1486

Planque N, Long Li C, Saule S, Bleau AM, Perbal B (2006) Nuclear addressing provides a clue for the transforming activity of amino-truncated CCN3 proteins. J Cell Biochem 99:105–116

Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM (2007) Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res: MCR 5:1001–1014
Rydziel S, Stadmeyer L, Zanotti S, Durant D, Smerdel-Ramoya A, Canalis E (2007) Nephroblastoma overexpressed (Nov) inhibits osteoblastogenesis and causes osteopoenia. J Biol Chem 282:19762–19772.

Sakamoto K, Yamaguchi S, Ando R, Miyawaki A, Kabasawa Y, Takagi M, Li CL, Perbal B, Katsube K (2002) The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J Biol Chem 277:29399–29405.

Sanseau J, Truchet S, Bauvois B (2003) Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing’s sarcoma cells. J Biol Chem 278:36537–36546.

Schutze N, Noth U, Schneidereit J, Hendrich C, Jakob F (2005) Differential expression of CCN-family members in primary human bone marrow-derived mesenchymal stem cells during osteogenic, chondrogenic and adipogenic differentiation. Cell Commun Signal: CCS 3:5.

Shimoyama T, Hiraoka S, Take moto M, Koshizaka M, Tokuyama H, Tokuyama T, Watanabe A, Fujimoto M, Kawamura H, Sato S, Tsuturin Y, Saito Y, Perbal B, Koseki H, Yokote K (2010) CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler Thromb Vasc Biol 30:675–682.

Sin WC, Tse M, Planque N, Perbal B, Lampe PD, Naus CC (2009) Matricellular protein CCN3 (NOV) regulates actin cytoskeleton via Notch signaling pathway. J Biol Chem 277:29405–29413.

Su BY, Cai WQ, Zhang CG, Martinez V, Lombet A, Perbal B (2001) The Matricellular protein CCN3 (NOV) regulates actin cytoskeleton by post-transcriptional mechanisms. J Cell Biochem 112:715–722.

Su BY, Cai WQ, Zhang CG, Martinez V, Lomboet A, Perbal B (2001) The expression of ccn3 (nov) RNA and protein in the rat central nervous system is developmentally regulated. Mol Pathol: MP 54:184–191.

Su JL, Chio J, Tang CH, Zhao M, Tsai CH, Chen PS, Chang YW, Chien MH, Peng CY, Hsiao M, Kuo ML, Yen ML (2010) CYR61 regulates BMP-2-dependent osteoblast differentiation through the [alpha]v[beta]3 integrin/integrin-linked kinase/ERK pathway. J Biol Chem 285:31325–31336.

Subramaniam MM, Lazar N, Navarro S, Perbal B, Liombart-Bosch A (2008) Expression of CCN3 protein in human Wilms’ tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies. Virchows Arch Int J Pathol 452:33–39.

Tabaries S, Dong Z, Amnis MG, Omeroglu A, Pepin F, Ouellet V, Rusvo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, Hallett M, Siegel PM (2011) Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 30:675–682.

Tan TW, Huang YL, Chang JT, Lin JJ, Fong YC, Kuo CC, Tsai CH, Chen YJ, Hsu HC, Cho DY, Chen YH, Tang CH (2011) CCN3 increases BMP-4 expression and bone mineralization in osteoblasts. J Cell Physiol 226:1128–1134.

Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y (2001) A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 20:5525–5532.

Tanaka S, Sugimachi K, Kameyama T, Maehara S, Shirabe K, Shimada M, Wands JR, Maehara Y (2003) Human WISP1v1, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37:1122–1129.

Tang N, Song WX, Luo J, Haydon RC, He TC (2008) Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466:2114–2130.

Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, Diigama D, Grim JE, Clurman BE, Bowtell DD, Lee JS, Gutierrez GM, Piscopo DM, Carty SA, Hinds PW (2004) Terminal osteoblast differentiation, mediated by runx2 and p27kip1, is disrupted in osteosarcoma. J Cell Biol 167:925–934.

Thomopoulos GN, Kyrkchiess V, Perbal B (2001) Immunocytochemical localization of NOV protein and ultrastructural characteristics of NC1-H295R cells. J Submicrosc Cytol Pathol 33:251–260.

Tong ZY, Briggstock DR (2006) Intrinsic biological activity of the thrombospondin structural homology repeat in connective tissue growth factor. J Endocrinol 188:R1–R8.

Tzeng HE, Chen JC, Tsai CH, Kuo CC, Hsu HC, Hwang WL, Feng YC, Tang CH (2011) CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin dependent pathway. J Cell Physiol 226:1128–1134.

Valcourt U, Gouttenoire J, Aubert-Foucher E, Herbage D, Mallein-Gerin F (2003) Alternative splicing of type II procollagen mRNA in chondrocytes is oppositely regulated by BMP-2 and TGF-beta1. FEBS Lett 545:115–119.

Vallacchi V, Rodolfo M (2009) Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix. Cell Adhes Migr 3:7–10.

Vandrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons M, Birnbaum D, Nguyen C, Theillet C, Cohen PA (2004) Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 32:397–414.

Vooreberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H (1991) Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 113:195–205.

Vorwerk P, Hohmann B, Oh Y, Rosenfeld RG, Shymko RM (2002) Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3)-IGFBP-3N- and C-terminal fragments, and structurally related proteins mac25 and connective tissue growth factor measured using a biosensor. Endocrinology 143:1677–1685.

Xie D, Nakachi K, Wang H, Elashoff R, Koefler HP (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61:8917–8923.

Yamaguchi A, Sakamoto K, Minamizato T, Kenichi K, Soichi N (2008) Regulation of osteoblast differentiation mediated by BMP, Notch, and CCN3/NOV. Jpn Dent Sci Rev 44:48–56.

Yang B, Effer RC, Perbal B, Firth SM (2006) The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology 147:5268–5274.

Yanagitag T, Kubota S, Kawaki H, Kawata K, Kondo S, Takeno-Yamamoto T, Tanaka S, Takigawa M (2007) Expression and physiological role of CCN4/Wnt-induced secreted protein 1 mRNA splicing variants in chondrocytes. FEBS J 274:1655–1665.

Yu C, Le AT, Yeger H, Perbal B, Alman BA (2003) NOV (CCN3) regulation in the growth plate and CCN family members expression in cartilage neoplasia. J Pathol 201:609–615.

Zhang R, Averboukh L, Zhu W, Zhang H, Jo H, Dempsey PJ, Coffey RJ, Pardee AB, Liang P (1998) Identification of cCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol 18:6131–6141.

Zhang XL, Wang Q, Gerald W, Huidis CA, Norton L, Smid M, Foekens JA, Massague J (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16:67–78.

Zuo GW, Kehs CD, He BC, Chen L, Zhang W, Shi Q, Zhang BQ, Kang Q, Luo J, Luo X, Wagner ER, Kim SH, Restegar F, Haydon RC, Deng ZL, Lhu HH, He TC, Luo Q (2010) The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 25:795–806.